Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Synaptic mechanisms of memory loss: novel cell adhesion molecules as therapeutic targets (MEMSTICK)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Switzerland,Belgium,Germany,Spain,United Kingdom,Poland,Denmark,Denmark
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2011-04-30
Duration (months): 39.0
Total project cost (EUR): 4138676.19
EU funding (EUR): 2970372.0
Participants: 9
Project status: CLOSED

Memory loss is a central symptom in different diseases, and represents a significant social and economic burden for a large percentage of European citizens. The molecular and neurobiological bases of memory deficits are largely unknown and there are currently no drugs available that can markedly decelerate or prevent memory decline. To address this major problem, this project will investigate the role of novel synaptic cell adhesion molecules (CAMs) in memory loss, and the therapeutic value of targeting these CAMs to restore memory function and associated neurobiological mechanisms at the synaptic level. The selection of novel synaptic CAMs is based on (1) recent evidence showing that they can recruit the synaptic machinery and form synapses; (2) the implication of CAMs, in general, in synaptic plasticity and memory, and (3) a direct link established between synaptic remodelling and memory formation. We have assembled a multidisciplinary consortium including excellent European researchers in this field, covering a wide range of structural, biochemical, electrophysiological and behavioural expertise. To understand memory loss, three domains have been selected as among the most prominent and widespread disease domains affecting memory and quality of life in our society: psychiatric disorders, the neurodegenerative disorder of Alzheimer&amp;amp;apos;s disease, stress and aging. For each disease domain, specific and validated animal models will be used to investigate memory loss on molecular, subcellular, cellular and functional levels. Our approach will result in the preclinical development and validation of mimetic peptides for novel synaptic CAMs as potential drug candidates to treat memory deficits or prevent memory decline. The current proposal offers the groundbreaking possibility to raise the bar in memory research by targeting novel molecules and developing effective drugs to treat memory disturbances based on their biological mechanism.

Keywords: memory loss,novel synaptic cell adhesion molecules,peptides,psychiatric disorders,stress,aging,alzheimer's disease,metalloproteases,synapses,spines,plasticity.
Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair (GENODISC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Israel,United Kingdom,Germany,Finland,Greece,Netherlands,Hungary,Italy,Slovenia
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2013-02-28
Duration (months): 60.0
Total project cost (EUR): 4007552.0
EU funding (EUR): 2997144.0
Participants: 10
Project status: CLOSED

Disorders arising from degeneration of the intervertebral disc are an enormous clinical and financial burden on European societies. Most of the burden arises from 10% of patients who become chronically disabled. Any factor which will improve treatment of back pain sufferers or prevent development of chronic disability would have an important impact both on society and in improving quality of life of patients. Improving diagnosis is the key. At present, 85% of patients have no clear diagnosis resulting in arbitrary treatments, usually surgical, which range widely from centre to centre and are often ineffective. Without clear diagnostic criteria, treatments and preventative measures cannot be targeted effectively. Patients may be subjected to unnecessary and expensive interventions or else denied treatment which could be beneficial Scientific advances in understanding the aetiopathology of these disorders are necessary for development of objective diagnostic criteria, rational application of present treatments and development of new therapies. Genodisc aims to contribute to improvement of patient care through improving diagnosis of disc-related pathologies both by more effective utilisation of present diagnostic information and by developing novel diagnostic tools. Through these new diagnostic methods, it aims to select patients at risk of chronic low back pain and spinal stenosis. It also aims to develop criteria for selecting patients who will benefit from newly emerging biological therapies for treating disc degeneration. The scientific advances underpinning improved diagnosis will arise from genotyping carefully phenotyped patients, from research into the processes of disc degeneration and from models of how these molecular processes lead to disc failure. This research will potentially provide biomarkers which will increase diagnostic specificity and provide targets for development of drug therapies.

Keywords: genotyping,biomarkers,diagnostic probe,nutrient transport,mri,phenotype,spinal stenosis,chronic back pain
Hybrid PET-MR system for concurrent ultra-sensitive imaging (HYPERIMAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Spain,Netherlands,Germany,Italy,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2011-09-30
Duration (months): 42.0
Total project cost (EUR): 7333956.0
EU funding (EUR): 4940000.0
Participants: 8
Project status: CLOSED

The HYPERImage project will develop a novel hybrid system for simultaneous whole-body PET/MR imaging for humans. It will advance the required Time-of-Flight (ToF) PET technology, and the software for MR mediated compensation of motion artefacts. The hybrid system will be validated in pre-clinical and initial clinical studies, for exemplary applications in cardiovascular diseases, and in breast cancer as one of the most relevant applications in oncology. For latter application, the concept will be extended from pure imaging towards image-guided therapy. Positron Emission Tomography (PET) is the most sensitive molecular imaging modality. Hybrid PET/CT systems using Computer Tomography (CT) to provide the anatomical reference for lesion localization have evolved to be the best choice for a number of applications in cardiology and oncology. However, PET/CT has drawbacks and limitations: CT is associated with radiation dose and lacks soft tissue contrast, and PET suffers from restrictions in small lesion detectability, both due to motion artefacts during the scan, and due to detector limitations. A hybrid combination of ToF-PET with a 3T MR has the potential to overcome these shortcomings, by fully exploiting the superior soft-tissue contrast of MR in combination with a new MR-compatible solid-state PET detector technology, and a sophisticated motion compensation enabled by concurrent acquisition of both MR and time-stamped PET data. In addition, the versatility of MR allows imaging of supplementary functional parameters like temperature, elasticity, and diffusion, enabling this new hybrid imaging concept to open up new fields of applications in therapy guidance and therapy response monitoring. The consortium consists of one large company, one SME, three academic partners and two research institutes from five different EU countries. It combines leadership in technology with pioneer experience in using biomedical imaging for diagnosis and therapy monitoring.

Keywords: hybrid imaging concurrent imaging pet mri silicon photomultiplier motion compensation attenuation correction early detection cancer cvd
Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors (UROMOL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,Spain,Netherlands,Sweden,Spain
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2013-07-31
Duration (months): 66.0
Total project cost (EUR): 3922796.0
EU funding (EUR): 2995347.0
Participants: 8
Project status: CLOSED

Bladder cancer is a recurrent and very prevalent cancer and it generates the highest cost per patient in Europe. New genomic methods have allowed identifying new markers with potential clinical application. However, due to the use of single-marker assays and poor study design, none of these markers has made it to the clinic. FGFR3 and PIK3CA mutations, expression profiles, and microsatellite alterations in tumor tissue and urine, as well as polymorphisms in immune response genes, are very promising biomarkers that predict a tumor being present in the bladder and its likelihood of progression to invade the muscle. Here, we propose to combine the best markers of bladder cancer outcome in a prospective multicenter validation study in Spain, the Netherlands, Sweden and Denmark as genetic predictors. Pre-validation of markers has been or will be made utilizing the world’s largest bladder cancer biobank (60,000 samples from 2500 patients). To achieve enough power to rapidly generate conclusive results, 2000 patients will consecutively be enrolled, and subjected to analysis, as well as follow-up for 2-4 years. The approach is a pre-defined, standard operating procedure based, prospective study with fixed end-points and testing relatively few independent variables on tumor tissue, urine and blood. To obtain a seamless introduction into the clinic we will use a mathematical approach in which the best markers are weighted based on disease models and nomogram construction, leading to a risk score applied to each patient at each visit. The team has a very strong track record in bladder cancer research, micro-array application, nomogram construction, and bio-banking. The validated biomarkers will lead to specific recommendations for changes in patient management based on the risk scores. We estimate saving of more than 40 mill Euros annually based on a reduced frequency of cystoscopies, as well as an increased survival and a better quality of life for the patients.

Keywords: bladder cancer non-muscle invasive disease outcome prediction nomograms risk scores
A European Consortium for Lysosomal Disorders (EUCLYD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Italy,Netherlands,United Kingdom,Sweden,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 3907480.0
EU funding (EUR): 2958310.0
Participants: 6
Project status: CLOSED

The EUCLYD consortium aims at developing a scientific network among outstanding communities of basic and clinical investigators in five European countries (Italy, Netherlands, UK, Sweden and Germany) to study various aspects of lysosomal storage diseases (LSD). LSDs are rare disorders (overall prevalence of 1/5000 to 1/8000), each due to a specific lysosomal enzyme deficiency, leading to intracellular storage of a variety of undegraded substrates (sphingolipids, glycosaminoglycans, glycoproteins and glycogen) in different tissues. Among the 40 to 50 LSDs presently known, EUCLYD will focus on Gaucher disease, Pompe disease, MPS VI and Multiple sulfatase deficiency, as prototypes of disorders with different stored materials in various organs and tissues outside the CNS. The issues to be investigated in the proposed project are: pathophysiology and mechanisms underlying the symptoms and leading to devastating clinical consequences; natural history; testing of novel therapeutic approaches. These issues will be addressed by patients studies and with mouse models recapitulating the phenotype of LSDs. Recent advances in the pathophysiology of LSDs point to the role of secondary processes triggered by substrate storage. A better understanding of these processes is crucial to identify new targets of therapy. Enzyme replacement and substrate reduction therapies were successfully introduced in the treatment of specific LSDs. However, pilot clinical trials should be supported by post-marketing studies to further assess the efficacy of these therapies and to develop standardized treatment protocols. To this purpose a precise knowledge of the natural history of LSDs is essential. Novel therapeutic strategies, such as enzyme enhancement and gene therapy are still under investigation in cell systems and in animal models. EUCLYD will provide further testing of these approaches in order to translate state of the art knowledge into clinical applications and reach patient's bedside.

Keywords: lysosomal disorders,enzyme replacement therapy,gene therapy,substrate reduction,enzyme enhancement therapy,autophagy
Identifying the Needs for Patients Partnering in Clinical Research (PATIENTPARTNER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Netherlands,United Kingdom,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 1009808.0
EU funding (EUR): 905177.0
Participants: 4
Project status: CLOSED

The aim of this 3-year Coordination Action will be to identify the patients’ needs for partnership in the clinical trials context. Moreover, this project will lead to both a well-organized and sustainable communication platform and guidelines to enable the mutual beneficial interactions between patients and clinical trials professionals. This aim will be realized through: I) Interviews, addressing patients (-organizations) that will identify preliminary needs in the clinical trials context from a patients’ perspective. These data are complemented with literature reviews and descriptions of best practices. The combined outcomes will be accessable on a centralized webbased database. II) Subsequent workshops addressing patients (and patient organizations), researchers and scientists, biopharmaceutical companies, regulators and other stakeholders in the clinical trials context. In these workshops, the conclusions from the interviews, literature studies and best practices will be challenged to draw ‘European’ viewpoints and consensus. On the specific website, attendees will be able to consult the outcomes from both the investigational phase and previous workshops. III) The establishment of the European Network of Patients partnering for Clinical Research (EN-PCR). Initially, EN-PCR will be responsible for addressing the high priority issues in this project: paediatric clinical trials, patient registries and biobanks, the Innovative Medicines Initiative (IMI) and ethical issues. Later on, EN-PCR will guarantee the sustainability of this project, being a permanent structure with a bi-directional purpose, both empowering patients and functioning as a one-stop shop for academic and biopharmaceutical research. IV) Further dissemination of the project results will be achieved by a Patient Guide for patient organizations, an Investigator Guide for organizers and sponsors of clinical trials, a List of Recommendations for regulators and a thematic website. The consortium will provide continued support to both EN-PCR and the PatientPartner website after this Coordination Action has ended. This project is implemented by key European and national patient network organisations, and a forum for Good Clinical Practice. It concurrently supports patient-centered clinical research and European biophamaceutical competiveness.

Keywords: patients,clinical research,needs,patient organizations
Novel secretion systems of Mycobacterium tuberculosis and their role in host-pathogen interaction (NOVSEC-TB)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Netherlands,Italy,Switzerland,South Africa,Ireland
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-06-30
Duration (months): 42.0
Total project cost (EUR): 3762443.2
EU funding (EUR): 2821726.0
Participants: 8
Project status: CLOSED

Tuberculosis is a major public health threat to the populations of Europe and the world. Mycobacterium tuberculosis, the etiological agent of the disease, can multiply and persist within phagocytic cells and this early event is of primary importance for the outcome of the infection. The main objectives of this proposal are to use highly innovative approaches in molecular and cell biology, biochemistry, immunology and imagery to elucidate the function and interplay of three families of immunogenic proteins of M. tuberculosis, the ESX, PE and PPE families. It was recently found that the ESX systems constitute novel secretion machineries that export major virulence factors and important diagnostic and protective antigens. While the ESX-1 system is responsible for the secretion of the prototypic ESX proteins, namely, the 6 kDa early secreted antigenic target (ESAT-6) and the 10 kDa culture filtrate protein (CFP-10), which are the most important proteins of M. tuberculosis involved in host-pathogen interaction, ESX-5 is implicated in the secretion of PE/PPE proteins. Restriction to pathogenic mycobacteria makes them highly interesting targets for host-pathogen interaction. The ESX-3 system appears to be essential. Thus, in this project we propose to --> analyse the global gene expression network of ESX-1, ESX-3 and ESX-5, --> determine the nature and diversity of the effector proteins they secrete, --> establish their mode of action and sub-cellular localisation, --> survey potential genetic variation in clinical isolates, --> assess their interaction with the immune system of the host, --> evaluate the suitability of ESX systems as drug targets, --> screen small molecules for their potential to inhibit ESX-mediated secretion. The proposed approach will generate major insights into the role of these proteins in pathogenicity that are of utmost importance for the development of new diagnostics, vaccines and therapeutic agents for tuberculosis prevention and control.

Keywords: tuberculosis,secretion,esat-6,cfp-10,antigens,diagnostic,drug target,pe/ppe proteins,immunity
Understanding and fighting metastasis via dissection of the Core Invasive Machinery (METAFIGHT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Finland,Spain,Sweden,Spain,France,Netherlands,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2010-12-31
Duration (months): 36.0
Total project cost (EUR): 3946206.0
EU funding (EUR): 2999609.0
Participants: 10
Project status: CLOSED

The co-operative Metafight project will perform functional studies to understand the dissemination and outgrowth of metastasis through systematic analysis of the Core Invasive Machinery contained within integrin-mediated ECM attachment structure. It includes a large and discretely localised intracellular signalling network which drives migration and invasion. Our strategy is based on the hypothesis that metastatic cells arise from molecular changes that alter the primary tumour architecture as well as the tumor microenvironment, by reversible modulation of cell adhesion, onset of signalling pathways and acquisition of novel migratory and invasive capacities. The Metafight Consortium is strengthened by established combined expertise on adhesion receptor signalling and availability of unique tumor cell and cancer animal model systems. We will characterise known and novel components of the Core Invasive Machinery, responsible for development and homing of metastasis, by innovative in vivo non-invasive imaging techniques. The Metafight project comprises seven major interrelated Work Packages (WP). WP1 is designed to investigate the molecular and functional architecture of the Core Invasive Machinery, from which depends tumour cell migration and eventually invasion. WP2 and WP3 screen for key modulators of metastasis formation in in vivo murine models, by non-invasive imaging techniques. WP4 is related to a comprehensive proteomic analysis of expression and phosphorylation of our candidate modulators in metastasis formation. WP1-4 feed into WP5, which builds upon and exploits knowledge generated in the first four WPs and translates it into existing pharmacological interventions to generate new candidate drugs. This will lead to patent filing and licensing strategies. WP6 and WP7 handle dissemination and management activities. The ultimate accomplishment will include improvement of health, reduction of health expenses, as well as creation of new jobs and economic benefit.

Keywords: metastasis,adhesion,integrin,signalling,migration,invasion,imaging,breast cancer,animal models
TOWARDS SAFE AND EFFECTIVE IMMUNOTHERAPY OF PERSISTENT LIFE-THREATENING FOOD ALLERGIES (FAST)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,Austria,United Kingdom,Spain,Denmark,Italy,Poland,Greece,Iceland,Netherlands,France,Denmark,Austria,Spain,Netherlands,Netherlands,Spain,Denmark
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-09-01
End date: 2017-05-31
Duration (months): 105.0
Total project cost (EUR): 4162294.18
EU funding (EUR): 2993752.0
Participants: 19
Project status: CLOSED

The FAST project aims at the development of safe and effective treatment of food allergies. It targets persistent and severe allergy to fish and fruit. Besides persistence and severity, this choice is based on prevalence and the importance of these foods for a healthy diet. Classical allergen-specific immunotherapy (SIT) for treatment of food allergy using subcutaneous injections with food extracts has proven to be effective but too dangerous due to anaphylactic side-effects. FAST will therefore develop a safe alternative by replacing food extracts with hypo-allergenic recombinant major allergens, the active ingredients of SIT. Both severe fish and fruit allergy are caused by a single major allergen, parvalbumin for fish and lipid transfer protein for fruit. This makes development of a novel biotechnological product feasible. Two approaches will be evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypo-allergenic versions of parvalbumin and lipid transfer protein will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), Phase I and II randomized double-blind placebo-controlled multi-center clinical trials will be performed. Two routes of administration will be evaluated, subcutaneous in case of fish and sublingual in case of fruit. The primary read-out will be the double-blind placebo-controlled food challenge. To understand the underlying immune mechanisms of subcutaneous and sublingual immunotherapy, these trials will be accompanied by in depth serological and cellular immune analyses, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST will improve the quality of life of food allergic patients by providing a safe and effective curative treatment that will end their dependence on avoidance and rescue medication.

Keywords: food allergy immunotherapy recombinant allergens hypo-allergens fish fruit clinical trials